Ponatinib
- TRADE NAME: Iclusig (Ariad)
- INDICATIONS: Chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor therapy
- CLASS: Tyrosine kinase inhibitor
- HALF-LIFE: 24 hours
FDA APPROVAL DATE: 12/14/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Antacids, Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Grapefruit Juice, Histamine H2 antagonists, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Proton pump inhibitors, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors or inducers, Telaprevir, Telithromycin, Voriconazole
PREGNANCY CATEGORY: D
VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 04/14/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
